Jonathan B. Siegel - Oct 8, 2024 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
Director
Signature
/s/ Lisa A. Conte, Attorney-in-Fact
Stock symbol
JAGX
Transactions as of
Oct 8, 2024
Transactions value $
$0
Form type
4
Date filed
10/10/2024, 09:52 PM
Previous filing
Aug 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Stock option (right to buy) Award $0 +26.5K $0.00 26.5K Oct 8, 2024 Common Stock 26.5K $1.29 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2 The option grant was approved by the issuer's board of directors on October 8, 2024.
F3 The options will vest 100% on the first anniversary of the grant date, so long as the reporting person continues to serve on the board of directors of the issuer and Napo Therapeutics, S.p.A., the issuer's subsidiary, as applicable.